

Using Novel Imaging to More Safely Treat Neuroendocrine Tumors

NCT06122610

Status	RECRUITING
Phase	Phase 1
Sponsor	University of Wisconsin, Madison
Enrollment	10 participants

Key Eligibility Criteria

Inclusion (1)

- Candidates for 177Lu-DOTATATE (Lutathera) treatment for somatostatin receptor-positive neuroendocrine tumor

Exclusion (3)

- Unable to lie flat during or tolerate PET/CT or SPECT/CT
- Known incompatibility to CT, SPECT, or PET scans
- Unlikely to comply with study procedures, restrictions and requirements and judged by the investigator that the participant is not suitable for participation in the study

Locations (1 total)

University of Wisconsin - Madison, Madison, Wisconsin, United States